GLP-1 Daily: Ozempic & Wegovy News
Ohio's Medicaid Rulebook Bars GLP-1s for Obesity; An AHA Abstract Pits GLP-1s Against Metformin in Prediabetes; Australia Clears the Wegovy Pill
Tuesday, November 3, 2026 · 8 min
An advocacy group is pushing Ohio to rewrite the rule that keeps its Medicaid program from covering GLP-1s for adult obesity, while a large, preliminary health-records study for the American Heart Association links GLP-1s to better prediabetes outcomes than metformin. Australia's drug regulator has also approved the Wegovy pill.
Listen
Show notes
An advocacy group is pushing Ohio to rewrite the rule that keeps its Medicaid program from covering GLP-1s for adult obesity, while a large, preliminary health-records study for the American Heart Association links GLP-1s to better prediabetes outcomes than metformin. Australia's drug regulator has also approved the Wegovy pill.
In this episode
- Group seeks Ohio Medicaid coverage for GLP-1 weight-loss drugs — Daytondailynews
“The Ohio Department of Medicaid is prohibited from covering GLP-1 medications specifically for the condition of obesity in adults due to a restriction in the Ohio administrative code, but a national organization is advocating for state officials to change this.”
- GLP-1 meds linked to lower diabetes, heart risks than standard diabetes prevention med | American Heart Association — American Heart Association
“GLP-1 (glucagon-like peptide-1 receptor agonists) medications, currently popular for weight-loss, may help prevent Type 2 diabetes and lower the risk of heart attack and stroke more than the standard diabetes prevention medication metformin among people with prediabetes,…”
- Watchdog’s huge call on weight-loss drug pill - Yahoo News Australia — Emma Kirk
“A Department of Health spokesman said the TGA approved the registration of a Wegovy oral tablet in 1.5mg, 4mg, 9mg and 25mg strengths.”